- Lexaria
Bioscience is helping to revolutionize efforts to provide common drug
substances in an ingestible method that avoids unhealthy practices such as
inhaled smoking or vaping
- Lexaria’s
DehydraTECH platform works to deliver the chemical compounds to the blood
stream at speeds comparable to inhalation methods, providing the means for
discrete use and avoiding frustrating waits for users with dependencies
- The
company recently obtained a patent in Australia that recognizes
DehydraTECH not only as a food and beverage platform, but also as a
potential means of pharmaceutical use for combatting select illnesses
- As
Canada prepares to introduce legalization of cannabis food and beverage
products next month, analysts forecast a market worth $2.7 billion a year
for edibles and alternative cannabis products, with extract products
including edibles comprising 60 percent of the total
As Canada prepares to roll out its ‘Cannabis 2.0’ wave of
product legalization focused on edible and drinkable forms of the plant’s core
ingredients less than a month from now, with the products themselves hitting
store shelves beginning in December, analysts are anticipating a consumables
market rife with opportunity for innovation. Deloitte predicts the Canadian market
for edibles and alternative cannabis products alone will be worth $2.7 billion
annually, and that cannabis extract-based products including edibles will make
up nearly 60 percent of that amount at $1.6 billion (http://ibn.fm/pxHkr).
Bioactive technology innovator Lexaria
Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is preparing to make its
presence known in this new marketplace, building on a relationship forged with
alcohol-free beer, wine and adult format beverage maker Hill Street Beverage
Company Inc. (TSX.V: BEER) to present its DehydraTECH-licensed products to
Canada’s licensed producers.
DehydraTECH is Lexaria’s patented platform for delivering
ingestible substances in a rapid-effect manner that works with all psychoactive
and non-psychoactive cannabinoids, nicotine, non-steroidal anti-inflammatory
drugs (NSAIDs) and fat-soluble vitamins, whether in the form of foods, liquid emulsions,
tablets or capsules (http://ibn.fm/Ope7W).
The brand formed in conjunction with Hill Street will
feature processed tetrahydrocannabinol (THC) and/or cannabidiol (CBD) powder
derived from cannabis or its less chemically psychoactive hemp variant.
Canada’s 2.0 regulations have been designed to sidestep some
of the health concerns that have arisen in parts of the United States where
cannabis edibles are manufactured, taking into particular account concerns
about the potential for infused candies, which are currently popular, to appeal
to children who may be less physically able to process cannabis substances than
adults (http://ibn.fm/pY5kP).
Lexaria’s technological stance is that it “promotes
healthier administration methods, lower overall dosing and higher effectiveness
of ingestible drugs and other beneficial molecules … (than) other delivery
methods for bioactive substances in widespread use today such as inhalational
delivery through smoking.”
In an interview with Forbes (http://ibn.fm/uCoMP) earlier this year regarding
DehydraTECH’s efforts to forge an alternative to smoking cigarettes for people
with a nicotine addiction, CEO Chris Bunka noted some of his own personal
motivation, stating, “Wherever there are many victims from past injustices,
there is a lot of anger and resentment that doesn’t go away easily. My father
also died from lung cancer just last year, so I am no fan.”
Lexaria’s non-combustion-based, non-inhalation-based
delivery method requires no chemicals or additives.
“We use a patented dehydration synthesis process to combine
the nicotine with simple ingredients like sunflower oil in a unique way,” Bunka
told Forbes. “It allows for the removal of the bitter taste often associated
with nicotine without the need for artificial flavors that are often appealing
to children. Moreover, tested in animals in 2018, we proved that DehydraTECH
could deliver nicotine to the bloodstream of an animal in as little as two
minutes. The fact that it is fast means that smokers might not be frustrated
waiting for their nicotine experience to begin, the way they have been with
traditional nicotine products such as gums and lozenges.”
Lexaria’s subsidiary structure for managing licensing for
differing molecular classes has not generated as much media buzz when it comes
to NSAID pain relievers such as aspirin and ibuprofen, or for fat-soluble
vitamins, but these common household remedies also have potential harmful
digestion effects and time-intensive concerns that DehydraTECH’s delivery tech
may be able to sidestep.
The company also announced recently that it received a new
patent in Australia for potential pharmaceutical applications of its
DehydraTECH for combatting ‘certain conditions’, including heart disease,
neurological diseases including Parkinson’s, hepatic (liver) diseases and
diabetes through the delivery of cannabinoids (http://ibn.fm/QOxfP).
Nicotine-containing edibles also showed the potential for
reducing Parkinson’s disease risk during testing in 2013 (http://ibn.fm/faHXq), showing
still further possibilities for Lexaria’s technology.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
